4D Molecular Therapeutics FDMT Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's accrued expenses?
- 4D Molecular Therapeutics (FDMT) reported accrued expenses of $22.87M in Q1 2026.
- How has 4D Molecular Therapeutics's accrued expenses changed year-over-year?
- 4D Molecular Therapeutics's accrued expenses increased by 41.1% year-over-year, from $16.2M to $22.87M.
- What is the long-term trend for 4D Molecular Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's accrued expenses has grown at a 26.3% compound annual growth rate (CAGR), from $8.37M to $26.87M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.